| Product Code: ETC7626537 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Sumit Sagar | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Ireland Clinical Oncology NGS Market Overview |
3.1 Ireland Country Macro Economic Indicators |
3.2 Ireland Clinical Oncology NGS Market Revenues & Volume, 2021 & 2031F |
3.3 Ireland Clinical Oncology NGS Market - Industry Life Cycle |
3.4 Ireland Clinical Oncology NGS Market - Porter's Five Forces |
3.5 Ireland Clinical Oncology NGS Market Revenues & Volume Share, By Technology, 2021 & 2031F |
3.6 Ireland Clinical Oncology NGS Market Revenues & Volume Share, By Workflow, 2021 & 2031F |
3.7 Ireland Clinical Oncology NGS Market Revenues & Volume Share, By Application, 2021 & 2031F |
3.8 Ireland Clinical Oncology NGS Market Revenues & Volume Share, By End-use, 2021 & 2031F |
4 Ireland Clinical Oncology NGS Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing incidence of cancer cases in Ireland |
4.2.2 Technological advancements in Next-Generation Sequencing (NGS) technology |
4.2.3 Growing demand for personalized medicine in clinical oncology |
4.3 Market Restraints |
4.3.1 High cost associated with NGS technology implementation and testing |
4.3.2 Lack of skilled professionals in the field of clinical oncology and NGS |
4.3.3 Regulatory challenges and stringent approval processes for NGS-based tests |
5 Ireland Clinical Oncology NGS Market Trends |
6 Ireland Clinical Oncology NGS Market, By Types |
6.1 Ireland Clinical Oncology NGS Market, By Technology |
6.1.1 Overview and Analysis |
6.1.2 Ireland Clinical Oncology NGS Market Revenues & Volume, By Technology, 2021- 2031F |
6.1.3 Ireland Clinical Oncology NGS Market Revenues & Volume, By Whole Genome Sequencing, 2021- 2031F |
6.1.4 Ireland Clinical Oncology NGS Market Revenues & Volume, By Whole Exome Sequencing, 2021- 2031F |
6.1.5 Ireland Clinical Oncology NGS Market Revenues & Volume, By Targeted Sequencing & Resequencing Centrifuges, 2021- 2031F |
6.2 Ireland Clinical Oncology NGS Market, By Workflow |
6.2.1 Overview and Analysis |
6.2.2 Ireland Clinical Oncology NGS Market Revenues & Volume, By Pre-Sequencing, 2021- 2031F |
6.2.3 Ireland Clinical Oncology NGS Market Revenues & Volume, By Sequencing, 2021- 2031F |
6.2.4 Ireland Clinical Oncology NGS Market Revenues & Volume, By Data Analysis, 2021- 2031F |
6.3 Ireland Clinical Oncology NGS Market, By Application |
6.3.1 Overview and Analysis |
6.3.2 Ireland Clinical Oncology NGS Market Revenues & Volume, By Screening, 2021- 2031F |
6.3.3 Ireland Clinical Oncology NGS Market Revenues & Volume, By Companion Diagnostics, 2021- 2031F |
6.3.4 Ireland Clinical Oncology NGS Market Revenues & Volume, By Other Diagnostics, 2021- 2031F |
6.4 Ireland Clinical Oncology NGS Market, By End-use |
6.4.1 Overview and Analysis |
6.4.2 Ireland Clinical Oncology NGS Market Revenues & Volume, By Hospitals, 2021- 2031F |
6.4.3 Ireland Clinical Oncology NGS Market Revenues & Volume, By Clinics, 2021- 2031F |
6.4.4 Ireland Clinical Oncology NGS Market Revenues & Volume, By Laboratories, 2021- 2031F |
7 Ireland Clinical Oncology NGS Market Import-Export Trade Statistics |
7.1 Ireland Clinical Oncology NGS Market Export to Major Countries |
7.2 Ireland Clinical Oncology NGS Market Imports from Major Countries |
8 Ireland Clinical Oncology NGS Market Key Performance Indicators |
8.1 Average turnaround time for NGS testing in clinical oncology |
8.2 Number of clinical trials utilizing NGS technology in Ireland |
8.3 Adoption rate of NGS-based tests by healthcare providers in clinical oncology |
9 Ireland Clinical Oncology NGS Market - Opportunity Assessment |
9.1 Ireland Clinical Oncology NGS Market Opportunity Assessment, By Technology, 2021 & 2031F |
9.2 Ireland Clinical Oncology NGS Market Opportunity Assessment, By Workflow, 2021 & 2031F |
9.3 Ireland Clinical Oncology NGS Market Opportunity Assessment, By Application, 2021 & 2031F |
9.4 Ireland Clinical Oncology NGS Market Opportunity Assessment, By End-use, 2021 & 2031F |
10 Ireland Clinical Oncology NGS Market - Competitive Landscape |
10.1 Ireland Clinical Oncology NGS Market Revenue Share, By Companies, 2024 |
10.2 Ireland Clinical Oncology NGS Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here